299 related articles for article (PubMed ID: 21275447)
21. A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
Brereton N; Bodger K; Kamm MA; Hodgkins P; Yan S; Akehurst R
J Med Econ; 2010 Mar; 13(1):148-61. PubMed ID: 20141380
[TBL] [Abstract][Full Text] [Related]
22. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis.
Hoy SM
Drugs; 2015 May; 75(8):879-86. PubMed ID: 25920500
[TBL] [Abstract][Full Text] [Related]
23. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
24. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Bokemeyer B; Hommes D; Gill I; Broberg P; Dignass A
J Crohns Colitis; 2012 May; 6(4):476-82. PubMed ID: 22398060
[TBL] [Abstract][Full Text] [Related]
25. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
[TBL] [Abstract][Full Text] [Related]
26. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
27. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Inflamm Bowel Dis; 2009 Jan; 15(1):1-8. PubMed ID: 18671232
[TBL] [Abstract][Full Text] [Related]
28. Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.
Russo L; Schneider G; Gardiner MH; Lanes S; Streck P; Rosen S
Eur J Clin Pharmacol; 2014 Jun; 70(6):709-17. PubMed ID: 24609467
[TBL] [Abstract][Full Text] [Related]
29. MMX mesalamine.
Baker DE
Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
[TBL] [Abstract][Full Text] [Related]
30. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
Danese S; Siegel CA; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2014 May; 39(10):1095-103. PubMed ID: 24641622
[TBL] [Abstract][Full Text] [Related]
31. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000544. PubMed ID: 23076890
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
[TBL] [Abstract][Full Text] [Related]
33. Budesonide Multi-matrix for the Treatment of Patients with Ulcerative Colitis.
Lichtenstein GR
Dig Dis Sci; 2016 Feb; 61(2):358-70. PubMed ID: 26541989
[TBL] [Abstract][Full Text] [Related]
34. [Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain].
Gisbert JP; Gomollón F; Méndez I
Gastroenterol Hepatol; 2016 Mar; 39(3):199-212. PubMed ID: 26072136
[TBL] [Abstract][Full Text] [Related]
35. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
[TBL] [Abstract][Full Text] [Related]
36. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
37. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
38. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Kruis W; Brandes JW; Schreiber S; Theuer D; Krakamp B; Schütz E; Otto P; Lorenz-Mayer H; Ewe K; Judmaier G
Aliment Pharmacol Ther; 1998 Aug; 12(8):707-15. PubMed ID: 9726382
[TBL] [Abstract][Full Text] [Related]
39. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
[TBL] [Abstract][Full Text] [Related]
40. The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Bezzio C; Fascì-Spurio F; Viganò C; Meucci G; Papi C; Saibeni S
Expert Rev Gastroenterol Hepatol; 2017 Jan; 11(1):33-41. PubMed ID: 27805459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]